Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
Bispecific (CD20×CD3)
Mosunetuzumab
Lunsumio · Mosun
A CD20×CD3 bispecific whose kidney risk runs through cytokine release and tumor lysis, not the tubule.
ModerateT-cell-engaging bispecific · approved 2022
Follicular lymphomaB-cell non-Hodgkin lymphoma
Signature kidney injury
Prerenal / Hemodynamic AKI
No direct tubular nephrotoxic signal. AKI is a downstream/case-level consequence of cytokine release syndrome (CRS, ~44% any-grade, almost all grade 1-2 and concentrated in cycle 1) and tumor lysis syndrome; renal-specific incidence is not quantified.
Source: Budde et al., Lancet Oncol 2022
Mechanism of kidney injury
Kidney injury is indirect. T-cell activation releases IL-6, IFN-gamma and TNF; the resulting fever, vasodilation, hypotension and capillary leak lower renal perfusion to produce hemodynamic/prerenal AKI. In parallel, rapid B-cell lysis can precipitate tumor lysis syndrome with hyperuricemia and hyperphosphatemia, driving intratubular urate/calcium-phosphate crystal deposition. Step-up (priming) dosing across cycle 1 is specifically designed to blunt the CRS peak that mediates this risk.
Clinical presentation
Rising creatinine in the setting of CRS (fever, hypotension, hypoxia, often with elevated CRP/ferritin/IL-6); with tumor lysis, hyperkalemia, hyperphosphatemia, hyperuricemia and hypocalcemia. Hypophosphatemia was a common grade 3-4 laboratory abnormality in the pivotal trial. Urinalysis is typically bland.
Onset
Early — during cycle 1 step-up dosing, coincident with CRS (first days to ~2 weeks).
Reversibility
Reversible
Anticancer mechanism
CD20×CD3 T-cell-engaging bispecific antibody that crosslinks CD3 on host T cells to CD20 on malignant B cells, forming an immunologic synapse that drives granzyme/perforin-mediated B-cell lysis. Approved for relapsed/refractory follicular lymphoma after two or more prior lines.
Management
Treat CRS with supportive care, IL-6 blockade (tocilizumab) and corticosteroids per grade; restore renal perfusion with isotonic fluids; manage tumor-lysis electrolytes (rasburicase for hyperuricemia, phosphate binders); provide supportive AKI care including renal replacement therapy if refractory.
Risk factors
- High tumor burden
- Bulky/rapidly proliferative disease
- Volume depletion
- Pre-existing CKD
- Concurrent nephrotoxins
Prevention
- Step-up (priming) dosing in cycle 1
- CRS monitoring with early tocilizumab and corticosteroids
- Tumor lysis prophylaxis (hydration, allopurinol or rasburicase) in high-risk patients
- Volume optimization before infusions
Note · Direct nephrotoxicity is not an established signal; renal risk is mediated by CRS and tumor lysis. Renal-specific data remain limited.
Clinical depth
Renal dose adjustment
No specific renal dose adjustment is defined; mild-to-moderate renal impairment is not expected to alter exposure of an IgG bispecific. No data in severe impairment/ESKD — dose on clinical grounds.
Dialyzability & ESKD dosing
Not dialyzable (~145 kDa IgG cleared by reticuloendothelial catabolism, not renal filtration). No supplemental dosing needed for HD/PD.
Differential diagnosis
Distinguish CRS-driven prerenal AKI (hypotension, fever, fluid-responsive, bland sediment) from tumor lysis AKI (urate/phosphate elevation, characteristic electrolytes) and from CAR-T/bispecific-associated collapsing glomerulopathy (nephrotic-range proteinuria — biopsy-described but rare). True drug-intrinsic tubular toxicity is not expected.
Monitoring
- Serum creatinine and electrolytes (K, phosphate, uric acid, calcium) before and during cycle 1 step-up dosing
- CRS vital signs and inflammatory markers (CRP, ferritin) during the priming phase
- Tumor lysis labs every 6-12 h in high-burden disease during initial dosing
Key trials & series
- GO29781 / Budde Lancet Oncol 2022 pivotal phase 2 (CRS 44%, mostly grade 1-2)
Clinical pearls
- The renal story here is hemodynamic and metabolic, not tubular — fix the CRS and the electrolytes and the kidney usually follows.
- Step-up dosing exists largely to flatten the cycle-1 CRS peak; most AKI clusters in that window.
- Hypophosphatemia is a frequent lab abnormality and can be multifactorial (tumor lysis correction, refeeding) — interpret in context.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Prerenal / Hemodynamic AKIElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of bispecific (cd20×cd3)s.
Immune / Infusion
CRS, infusion reactions, irAEs, anaphylaxis
- Cytokine release syndrome
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- ICANS / neurotoxicity
Hematologic
Cytopenias, thrombosis, TMA
- Cytopenias, hypogammaglobulinemia
Evidence
7 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkSafety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.Budde LE et al. · Lancet Oncol 2022 · PMID 35803286Pivotal trial: CRS in 44% (mostly grade 1-2, cycle 1); hypophosphataemia common grade 3-4. Basis for indirect renal risk.PMIDMosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting.Cao Y et al. · J Hematol Oncol 2023 · PMID 37381053Review of efficacy and the CRS-dominant safety profile of mosunetuzumab.PMIDAcute Kidney Injury in Cancer Immunotherapy Recipients.Joseph A et al. · Cells 2022 · PMID 36552755Onconephrology review detailing CRS-, tumor-lysis- and infiltration-mediated AKI with bispecific T-cell engagers and CAR-T.PMIDCollapsing Focal Segmental Glomerulosclerosis and Acute Kidney Injury Associated With Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Case Report.Acharya R et al. · Kidney Med 2021 · PMID 34939018Biopsy-proven collapsing glomerulopathy and AKI with CRS, including after the CD19xCD3 engager blinatumomab — illustrates the rare glomerular pattern.PMIDEmergencies in Hematology: Why, When and How I Treat?Duminuco A et al. · J Clin Med 2024 · PMID 39768494Frames tumor lysis (electrolytes, AKI) and CRS as hematologic emergencies in the bispecific/CAR-T era.PMIDTumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.Howard SC et al. · Ann Hematol 2016 · PMID 26758269Systematic review of TLS risk and prophylaxis across novel hematologic agents.PMIDAnticancer Drug-Induced Acute Kidney Injury.Izzedine H et al. · Kidney Int Rep 2017 · PMID 29318217Onconephrology reference framing prerenal/hemodynamic and tumor-lysis mechanisms of AKI.
Related agents
Other agents sharing the same signature kidney injury.